


Editorial

Welcome to Seminars in Thrombosis & Hemostasis 2023

Emmanuel J. Favaloro, PhD, FFSc (RCPA)¹ 

¹Department of Haematology, Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW, Australia

Semin Thromb Hemost 2023;49:1–2.

Welcome to the start of another year with *Seminars in Thrombosis & Hemostasis* (STH), this being my 15th year anniversary as Editor-in-Chief. As always, I will again sincerely thank all past and current contributors to STH over the many years, as well as to all past, current, and future Guest Editors who commit their time to advance STH, and of course the current and past Editorial team. There has been no major overhaul of the editorial team at time of writing, although some adjustments will continue to occur over coming years.

I also take this opportunity to once again thank the journal production team at Thieme Medical Publishers for their high production standards and for facilitating both the print and online issues of the journal, and in particular, Mansi Agarwal, the new Production Editor for STH, and her production team.

This now annual Editorial represented, in the past, an opportunity to reflect on our journal's Impact Factor and other journal metrics. However, because of the continuing move to online publication ahead of print publication, a separate detailed editorial was published on these topics late last year.¹ In addition to detailing information on the journal's Impact Factor, in part in comparison to trends from other

journals publishing in the Thrombosis and Hemostasis space, I also shared many other publication metrics. I will summarize the information on Impact Factor as follows: (1) the 2021 Impact Factor for STH was 6.398, which marks a substantive increase over the 2020 Impact Factor, which was 4.180, and the 2019 Impact Factor, which was 2.892; (2) the previous highest Impact Factor (4.524) was 10 years ago in 2011; and (3) in general, most thrombosis and hemostasis focused journals showed an increase in Impact Factor from 2020 to 2021, largely on the back of several highly cited coronavirus disease 2019 (COVID-19)-related papers. It should also be noted that the calculations for Impact Factors have evolved over recent years to ensure better representation of online publications, which often precede print versions by several months. Indeed, some journals now only publish online.

As I always do for the Welcome Editorial, I confirm that we, as always, will continue to develop plans for the future content of this journal, and we are confident that our journal will be able to continue to bring its readers the high-quality journal that is expected of us. Currently confirmed topics for issues that we plan to publish over the next 12 or so months are listed in ► **Table 1**.

Table 1 Current planned topics for future issues of *Seminars in Thrombosis & Hemostasis* include

• Editorial compilations (continuing series focusing on bleeding disorders or laboratory aspects of thrombosis and hemostasis)
• Recent advances in thrombosis and hemostasis (continuing series focusing on thrombotic disorders)
• Laboratory diagnostics for thrombosis and hemostasis (continuing series focusing on laboratory diagnostics)
• Contact activation: An important but underrecognized pathway of hemostasis
• Emerging use of viscoelastography in thrombosis and hemostasis: a challenge to conventional coagulation tests
• Optimizing and extending the risk adapted management of acute pulmonary embolism beyond the acute phase
• Platelets (and hemostatic effectors) in precision medicine
• Maternal and neonatal hemostasis
• Celebrating 50 years of <i>Seminars in Thrombosis and Hemostasis</i> (a series of issues celebrating 50 years of STH)

Address for correspondence
Emmanuel J. Favaloro, PhD, FFSc (RCPA), Department of Haematology, Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW, 2145, Australia (e-mail: emmanuel.favaloro@health.nsw.gov.au).

Issue Theme Maintaining Hemostasis and Preventing Thrombosis in COVID-19—Part IV; Guest Editors: Emmanuel J. Favaloro, PhD, FFSc (RCPA), Leonardo Pasalic, FRCPA, FRACP, PhD, and Giuseppe Lippi, MD

© 2023, Thieme. All rights reserved.
Thieme Medical Publishers, Inc.,
333 Seventh Avenue, 18th Floor,
New York, NY 10001, USA

DOI <https://doi.org/10.1055/s-0042-1759685>.
ISSN 0094-6176.

Naturally, we recognize the need to retain some flexibility in our plans, and to potentially add additional material of current interest and controversy as the need arises. Notably, COVID-19 continues to create havoc for us, although many of us have returned to routines similar to pre-COVID times. Nevertheless, the pandemic has led us to create a continuing series of issues specifically focused on thrombosis and hemostasis in COVID-19,²⁻⁴ and now also including the current issue of the journal. It is likely that as we head back to “business as usual,” this will be the last issue of STH specifically focused on COVID-19. In the future, COVID-19 material accepted for publication in STH will be placed in our standard “non-themed” composite issues. Nevertheless, we look forward to another interesting year of reading in 2023.

Conflict of Interest

None declared.

References

- 1 Favalaro EJ. New Seminars in Thrombosis and Hemostasis (STH) 2021 Impact Factor, most highly cited papers, and other journal metrics. *Semin Thromb Hemost* 2022;48(06):634–642
- 2 Favalaro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part I. *Semin Thromb Hemost* 2020;46(07):757–762
- 3 Favalaro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part II. *Semin Thromb Hemost* 2021;47(04):333–337
- 4 Favalaro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part III. *Semin Thromb Hemost* 2022;48(01):3–7